Protalix BioTherapeutics Sells Its Share in Collaboration Agreement for ELELYSO and a 6% Equity Stake in Protalix to Pfizer for a Total of $46 Million
October 13, 2015 07:30 ET
|
Protalix BioTherapeutics, Inc.
Protalix to Use Funds to Aggressively Push Its Clinical Pipeline Forward and Execute Its New Strategy of Developing Clinically Superior Biologics
Protalix Receives All Rights to ELELYSO in...
Protalix BioTherapeutics to Explore Non Alcoholic Steato Hepatitis (NASH) as an Indication for Its PRX 106 Oral Anti TNF
October 05, 2015 08:00 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Oct. 5, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today pre-clinical data for PRX-106 in Non-alcoholic Steatohepatits (NASH), a...
Protalix BioTherapeutics Reports Positive Phase I/II Interim Clinical Data on the 1mg/kg Cohort of PRX-102 for Fabry Disease
September 09, 2015 07:00 ET
|
Protalix BioTherapeutics, Inc.
Positive efficacy data across all disease parameters
Positive safety data with low level of antibody formation
End of Phase II meeting with FDA scheduled before year end
CARMIEL, Israel, Sept....
Protalix BioTherapeutics Reports Second Quarter 2015 Financial Results
August 10, 2015 16:30 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Aug. 10, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), today reported financial results for the second quarter of 2015.
"We recently reported...
Protalix BioTherapeutics Reports Positive Phase I Clinical Study Results for PRX-106 Oral Anti-TNF
August 03, 2015 07:30 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, Aug. 3, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today positive clinical study results from the Company's Phase I trial of PRX-106,...
Protalix BioTherapeutics Announces AIR DNase(TM) Data Presented at the 38th European Cystic Fibrosis Conference
June 12, 2015 07:30 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, June 12, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) announced today that pre-clinical data for AIR DNaseTM (PRX-110) for the treatment of Cystic...
Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences
May 14, 2015 07:30 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, May 14, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE:PLX), today announced that Moshe Manor, the Company's President and Chief Executive Officer, will...
Protalix BioTherapeutics Reports First Quarter 2015 Financial Results
May 07, 2015 16:30 ET
|
Protalix BioTherapeutics, Inc.
- Losses narrowed by 19%
- Interim data and full results for PRX-102 expected in the Second Half of 2015
CARMIEL, Israel, May 7, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE...
Protalix BioTherapeutics Reports Full Year 2014 Financial Results and Provides Corporate Update
March 12, 2015 16:30 ET
|
Protalix BioTherapeutics, Inc.
CARMIEL, Israel, March 12, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), today reported financial results for the year ended December 31, 2014 and provided an...
Protalix BioTherapeutics Presents Additional Positive Phase I/II Interim Clinical Data on PRX-102 for Fabry Disease at the WORLD Symposium
February 12, 2015 07:30 ET
|
Protalix BioTherapeutics, Inc.
New Positive Clinical Data on Cardiac and Kidney Functions
Detailed Positive Clinical Data on All Disease Parameters
CARMIEL, Israel, Feb. 12, 2015 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics,...